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Hyaluronic acid and tendon lesions
by limited but encouraging short-term clinical re-
sults on pain and function. However, controlled
randomised studies are still needed.
KEY WORDS: hyaluronic acid, tendinopathy, tendon, heal-
ing, cicatrization.
Introduction
Tendon lesions are very common in sportsmen and
physical workers1. Their physiopathology is multifac-
torial, including intrinsic and extrinsic factors, which
can be modified or not2. Even if detrained tendons
present the same histological structure as chronic
tendinopathies, however, this condition remains an
overuse pathology which is often difficult to treat2. For
this reason, various new treatment have been devel-
oped1 such as platelet-rich plasma (PRP)3 or growth
factors4 infiltrations. Recently, the anti-inflammatory
and lubrication properties of HA have also been sug-
gested for the treatment of these pathologies5.
Hyaluronic acid (HA) is a polysaccharide with a high
molecular weight (between 100 kDa and 10 MDa),
mainly found in the extracellular matrix where it plays
different roles at various places in the organism5. Its
half-life is only three to five minutes in the circulation,
less than a day in tissue, and between one and three
weeks in cartilage. This speed of renewal means that
this polymer is constantly synthesised and degrad-
ed5. HA can be categorised into three groups based
on molecular weight:
- low molecular weight: MW < 1MDa;
- medium molecular weight: 1MDa < MW < 2MDa;
- high molecular weight: MW > 2MDa.
HA ensures the viscoelasticity of liquid connective tis-
sues such as the synovial joint and the corpus vit-
reum of the eye5. As a result of this ability, its role in
the body is, among other things, to bind to water and
to lubricate mobile parts of the body such as the
joints and muscles5. Intra-articular injections of syn-
thetic HA are widely used in the medical treatment of
osteoarthritis6-8.
Industrially, HA is obtained through two different pro-
cedures:
- extraction from rooster combs, after grinding and
chemical treatment5;
- purification and bacterial fermentation5.
The viscosity of the gel which is obtained is propor-
tional to the length (molecular weight, expressed in
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Introduction: recently, the viscoelastic proper-
ties of hyaluronic acid (HA) on liquid connective
tissue have been proposed for the treatment of
tendinopathies. Some fundamental studies show
encouraging results on hyaluronic acid’s ability
to promote tendon gliding and reduce adhesion
as well as to improve tendon architectural organ-
isation. Some observations also support its use
in a clinical setting to improve pain and function.
This literature review analyses studies relating
to the use of hyaluronic acid in the treatment of
tendinopathies.
Methods: this review was constructed using the
Medline database via Pubmed, Scopus and Google
Scholar. The key words hyaluronic acid, tendon
and tendinopathy were used for the research.
Results: in total, 28 articles (in English and
French) on the application of hyaluronic acid to
tendons were selected for their relevance and sci-
entific quality, including 13 for the in vitro part, 7
for the in vivo animal part and 8 for the human
section.
Conclusions: preclinical studies demonstrate en-
couraging results: HA permits tendon gliding, re-
duces adhesions, creates better tendon architec-
tural organisation and limits inflammation. These












termine how quickly the product degrades after im-
plantation.
One major absolute contraindication is hypersensitivi-
ty to one of the ingredients. Potential undesirable
side-effects are pain, a feeling of heat, haematoma,
redness and swelling.
Material and methods
This literature review was constructed using the Med-
line database via Pubmed, Scopus and Google
Scholar, according to the recommendations of the
Journal9. Articles published in English and French, up
to the 30th of September 2015, were found using the
following key words alone or in combination:
hyaluronic acid, hyaluronan, tendon, tendinopathy,
treatment (in English) and acide hyaluronique, ten-
don, tendinopathie, traitement (in French). In total,
only 28 articles on HA as applied to tendons were se-
lected for their relevance and scientific quality: 13 for




Even if the first published paper studying the effect of
HA on tendons of rabbits has not shown any effect on
the functional strength of tendons after healing in vi-
tro10, several Authors have sought to identify the abil-
ity of HA to improve tendon gliding.
Sun et al. used 30 canine peroneus longus, ran-
domised into five groups, and immersed for 30 sec-
onds in one of the following five solutions: saline so-
lution, gelatin, carbodiimide and HA (cd-HA) and
gelatin (cd-gelatin) and cd-gelatin-HA11. The tendons
were first placed in an incubator at 100% humidity at
37°C, before being wrapped in damp cloths for one
hour. Gliding resistance for each tendon was mea-
sured before the surfaces of the tendons were coat-
ed in the various solutions. After 500 cycles, gliding
resistance for the tendons coated in saline solution
increased significantly, by a factor of 10, while the
cd-gelatin and cd-gelatin-HA did not significantly
change. In addition, under microscopy, the surface of
the tendons in the saline, gelatin and cd-HA solu-
tions were rough, presenting a network of disorgan-
ised fibres. In contrast, the surface of the tendons
immersed in the gelatin-cd-HA solution appeared
smoother than in the other groups. These observa-
tions were confirmed by the study of Nishida et al.,
which suggest that HA may improve the gliding func-
tion of canine flexor tendons12.
Taguchi et al. wanted to identify whether these re-
sults could be transposed to human tendons13. They
used 16 human extrasynovial palmaris longus ten-
dons which were divided into two and then immersed
randomly in one of the following four solutions: saline
solution, carbodiimide-gelatin-HA (cg-gelatin-HA),
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carbodiimide-gelatin-lubrucin and cd-gelatin-HA-lu-
brucin. The results, after 1,000 flexion/extension cy-
cles, show that the tendons treated with saline solu-
tion presented significantly higher gliding resistance
than other groups. These findings, suggesting that
HA may limit tendon adhesions, has already been ob-
served in a previous study of Akasaka et al14.
In addition to its effects on tendon biomechanics, the
researchers looked at the influence of HA on tendon
regeneration.
Yamada et al. sought to determine the influence of
HA on cell proliferation and mRNA expression of type
I and type III procollagens15. They used tendons from
10 subjects suffering from rotator cuff disease who
had undergone surgical repair to the cuff. For each
fragment, the tendon tissue was separated from the
synovial tissue, cut into small pieces and cultured in
solutions containing various concentrations of HA
(1.0 to 5.0 mg/mL). The results showed HA binding to
its receptors and a reduction in cell proliferation in a
dose-dependent manner in comparison with untreat-
ed cells. In addition, the expression level of procolla-
gen α1 (I) mRNA did not significantly reduce in con-
trast to the expression of procollagen α1 (III) mRNA
in a dose-dependent manner.
Another study by Shimpuku et al. analysed the suture
site of the supracoracoid tendon in chickens after in-
jection of HA16. As well as confirming that HA treat-
ment does not increase the production of α1 (I) pro-
collagen, the team was able to show early restoration
of tendon continuity at the laceration site in compari-
son with the control group treated with saline solution.
Wiig et al. had compared the effect of HA on cell pro-
liferation and synthesis of matrix component in in-
trasynovial deep extensor tendons and extrasynovial
peroneus tendons of rabbits17. They observed that HA
modulates cell proliferation unequally in intra- and ex-
trasynovial tendons, but without affecting the matrix
component synthesis. This can be partly explained by
a difference in biochemical composition and cellular
capacities of tendons and by a possible difference in
HA sensitivity and in its mechanism of action.
Osti et al. had compared 4 different HA preparation by
their molecular weight on human tendon derived cells
from rotator cuff tears18. They observed that all the HA
increased the cell viability and the proliferation at 24
hours compared to control cells (without HA). Further-
more, the synthesis of collagen type I was stimulated
over 14 days, without increase in collagen type III.
However, these observations were significantly higher
in the high molecular weight HA groups.
Neumann et al. looked at the effects of HA on proin-
flammatory action caused by advanced glycation
endproducts (AGEs)19. The team compared the effi-
cacy of a preparation of HA with a ‘high’ molecular
weight (HMW-HA - >1.2MDa) to a preparation of HA
with a low molecular weight (LLW-HA - 0.2-0.5MDa)
on the production of AGEs and activation of proin-
flammatory cytokines on murine macrophages. Their
results show that HMW-HA, with a molecular weight
greater than 1.2 MDa, inhibits the inflammation sig-












this effect reduces with the molecular weight of HA.
Moreover, the results show that low molecular weight
HA (<0.5MDa) is proinflammatory.
Tanimoto et al. studied the effect of proinflammatory
cytokines on HA-synthetase (HAS) mRNA expression
using rabbit synovial membrane cells, cultured in in-
flammatory conditions IL1-β and TNF-α were used20.
Their results showed that proinflammatory cytokines
increase HAS mRNA expression and, consequently,
may contribute to the accumulation and fragmentation
of HA. Low molecular weight HA molecules no longer
played their lubricating role in an optimal way. A study
by Smith et al. highlighted the effect of adding ex-
ongenous HA to endogenous HA synthesis in synovial
fibroblasts21. Human synovial fibroblasts obtained dur-
ing biopsies or arthroplasties were cultured. Different
molecular weights of HA were then added. The results
clearly showed that in vitro HA synthesis by these
cells increased when the concentration and molecular
weight of the added HA was increased.
The recent study of Nakamura et al., comparing the
effects of corticosteroids or HA used in subacromial
injection on cell proliferation, in human tendon fibrob-
lasts from rotator cuff tears and in rats after surgical
lesion, demonstrated that HA possesses anti-inflam-
matory and anti-adhesive activities in tendon and
synovial fibroblasts. In contrast to CS, HA caused no
adverse effects and appears to be relatively safe22.
Animal experiments
Zhao et al. wanted to identify the effect of HA on the re-
duction of adhesions and on functional improvement af-
ter failed tendon reconstruction23. To simulate this situ-
ation, 28 flexor tendons from the 2nd and 5th digits of
dogs were lacerated and repaired. One graft tendon in
each dog was treated with an injection of saline solu-
tion, and the other with an injection of HA (1%) com-
bined with lubricin (cd-HA-lubricin). Six weeks after the
surgical operation, the allografts treated with cd-HA-lu-
bricin showed decreased adhesions at the proximal ex-
tremity, improved digit function and increased graft glid-
ing ability. However, rupture resistance at the proximal
and distal repair sites was lower in the treated group
than in the control group. Moreover, histological analy-
sis showed delayed healing in the treated group. A
study by Oryan et al. aimed to assess the effects of
high molecular weight (1.6MDa) HA (0.9%) on the heal-
ing of flexor tendons in the digits of rabbits after lesion
and repair through surgical suture24. Injections were
administered to 40 rabbits, randomly divided into two
equal groups of injured treated with HA and injured un-
treated. The results showed a significant reduction in
the diameter of the treated tendons and an increase in
echogenicity. In addition, the dry weight of the injured
tendons had significantly increased in comparison with
the non-treated tendons. The treatment also significant-
ly improved tenoblast numbers and the diameter and
density of collagen fibrils. Yoshida et al. also demons-
trated that high molecular weight HA (2700 kDa) was
effective for pain relief and for partial restoration of the
patellar tendinopathy in a rat model, compared to saline
or nothing (control group)25.
The Liang et al. team wanted to show the effect of the
presence of tenocytes when injecting HA into the
Achilles tendons of rats at an early healing stage26.
After transection and suture of the Achilles tendon, 96
rats were randomised into three groups: one group
(THA) received an injection of 1.0 kDa HA (1.5%) with
tenocytes (5x105), one HA group received the same
injection without tenocytes, and a control group re-
ceived a saline solution injection. A significant differ-
ence in recovery, tendon stiffness and locomotive abil-
ity was observed in the THA group. The THA group al-
so had a shorter healing time, ending the inflammato-
ry phase and starting the proliferation phase from day
7, while the non-treated and HA groups were still in
the inflammatory phase of the healing process on day
7. Acceleration of the inflammatory process through
injection of THA may be the main reason for this func-
tional improvement. In addition, the few differences
measured between the tendons treated with HA and
the tendons injected with saline solution may be ex-
plained by the low molecular weight (1.0 kDa) of HA
used. This study shows that adding tenocytes to HA
injections may positively influence tendon repair by re-
ducing inflammatory response time. However, the use
of low molecular weight HA in this study makes com-
parisons with THA difficult. Moreover, the use of THA
appears to be more appropriate for surgical interven-
tions on tendons than in tendinopathies, given the
constraints of removing tenocytes.
The recent series of Salamanna et al. comparing the
mechanobiology of patellar tendons of rats randomi-
zed into 3 groups (untrained, trained and detrained),
demonstrate that discontinuing training activity in the
short term alters tenocyte synthetic and metabolic ac-
tivity and that repeated peri-patellar infiltrations of HA
during detraining allow the maintenance of tenocyte
anabolic activity27: higher proliferation rate and viabil-
ity, and increased synthesis of C-terminal-propeptide
of type I collagen, fibronectin, aggrecan, tenascin-c
and matrix-metalloproteinase-3. These results are
reinforced by those of Frizziero et al., comparing the
same groups, who demonstrated that HA is effective
in the maintenance of the structural properties of pa-
tellar tendon and enthesis in detrained rats28.
Contrary of the in vitro observation, Yamaguchi et al.
suggested that both hyaluronic acid and steroid injec-
tions suppressed of inflammation (evaluated by the ex-
pression of calcitonin generelated peptide - CGRP) in a
rotator cuff of rats, which thought to be provided pain
relief (analyzed by the gait analysis)29. While there
were no significant differences, the suppression of
CGRP expression and the improved gait after hyaluron-
ic acid and steroid injections suggested that both meth-
ods were effective for rat rotator cuff tear model.
Human experiments
Meloni et al. examined the effect of periarticular injec-
tion of HA in patients suffering from a supraspinatus
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tendinopathy30. A total of 56 patients participated in
the study and were randomised into two equal groups:
one group treated with an injection containing 20 mg
of HA (concentration: 20mg/2ml, molecular weight:
0.5-0.7 mDa) in 2 ml of lidocaine (1%) and 2 ml of
physiological liquid (0.9%) and a control group receiv-
ing an injection of 4 ml of physiological solution
(0.9%). Lidocaine is used to reduce pain due to the in-
jection. After the first injection, the injection was re-
peated once a week for four weeks. During this peri-
od, analgesics were prescribed for three days after
each injection. After one year, 19 of the 28 patients
who had received HA were satisfied with their treat-
ment, while all patients in the control group said they
were dissatisfied after their injections. Joint extension
remained identical throughout the follow-up. At
months 1 and 3 following the injection, a significant
improvement in pain in the treated group in compari-
son with the control group was noted. However, after
one year, this pain had increased in the treated group.
Moreover, no significant difference in tendon structure
was observed during the ultrasound scan between the
two groups either at the start or at the end of the fol-
low-up.
Petrella et al. treated 330 competitive racquet sports
athletes presenting with chronic lateral epicondylosis
for more than three months31. Two injections were
administered one week apart, into the subcutaneous
tissue and muscle one centimeter from the lateral epi-
condyle toward the primary point of pain using a two-
dimensional fanning technique: the treated group re-
ceived an injection of 1.2 ml of HA (high but unspeci-
fied molecular weight) at 1% and the control group re-
ceived a saline solution of 1.2 ml. Follow-up examina-
tions were conducted after 7, 14, 30, 90 and 356
days and consisted of a VAS at rest and during mea-
surement of grip strength using a Jamar dynamome-
ter, an elbow disability scale, a functional scale, a
satisfaction scale and a measure of time to return to
pain-free sport. After one year, there was a significant
improvement in pain at rest and grip. Moreover, the
scores on all scales had significantly improved in the
treated group in comparison with the control group.
The time to return to pain-free sport was assessed at
18 days (+/-11 days) in the treated group.
The efficiency of an HA injection for treating patellar
tendinopathies was determined in fifty patients32 with
stage 2 or 3 using Blazina’s classification33. The in-
jected solution contained 2.5 mg of HA with a molec-
ular weight of 900 kDa in 2.5 ml of physiological liquid
and 1 ml of lidocaine. The effectiveness was as-
sessed on the basis of pain during sport, using the
modified Roles and Maudsley scores34. After treat-
ment, 54% of cases were ‘excellent’, and 40% of cas-
es were ‘good’. The results of this study are based on
the subjective views of the athletes and their trainers.
With a view to reducing post-surgical adhesions of
digital flexor tendons, Riccio et al. studied 45 patients
randomly assigned to two groups: a control receiving
a placebo (n=10), and a treated group receiving an
injection of HA (high but unspecified molecular
weight) (n=26)35. All patients were assessed at 30,
60, 90 and 180 days after surgery by testing active
motion, with functional capacity being assessed using
the quick-DASH questionnaire and the number of
working days lost after surgery. Patients in the treat-
ed group showed better recovery of digital motion at
all time intervals (improvement of 27% in the HA
group compared to 10% in the control group, and 43
to 28% respectively at day 180), and returned to work
earlier. However, no significant difference could be
shown in terms of functional score between the two
groups.
More recently, HA injections has been used to treat
the flexor muscle in the index finger after surgical su-
ture36. 11 were treated with three HA injections (0.4
ml of high molecular weight: 1.0-2.9 MDa and high
concentration: 15 mg/ml) and 11 received a placebo
saline solution of identical volume. Three injections
were administered: one at the time of the surgical in-
tervention and two others one week apart. The two
groups followed the same rehabilitation protocol after
the operation. The results showed no differences be-
tween the two groups in terms of extension after
three weeks. However, at three months and over the
long term, significant functional improvement of total
active range of joint motions (p=0.002 and p=0.001
respectively) was noted in the treated group in com-
parison with the placebo.
The short- and long-term effect of intra-articular injec-
tion of HA in patients suffering from supraspinatus
tendinopathy37 was assessed in 24 patients ran-
domised into two groups, each received three injec-
tions of 2 ml of HA (16 mg/2 ml with a molecular
weight of 6.0 MDa), following traditional physical ther-
apy treatment. TENS current, ultrasound therapy,
thermotherapy (hotpack) and exercises at home
(movements, stretches and eccentric exercises). Fol-
low-up consisted of algo-functional score, measure-
ment of active and passive joint extension conducted
at three weeks, three months and four years post-in-
jection. A significant improvement in most of the pa-
rameters measured was seen within both groups, but
no significant difference was observed for the pre-in-
jection VAS in comparison with the VAS conducted at
three weeks and three months post-injection.
The series of Merolla et al. enrolled 48 patients with
rotator cuff tendinopathy for more than 4 months ran-
domized into 2 groups: one group with 2 ultrasound-
guided subacromial injection of HA (N=25) 14 days
apart and one group with only a rehabilitation pro-
gram (N=23)38. The follow-up went up to 6 months.
They observed that subacromial HA injections was
more effective on pain and algofunctional scores than
rehabilitation alone, and this injection was a safe
treatment for patients suffering from rotator cuff
tendinopathy.
A recent study of Kumai et al. evaluated the effects of
a 2,5 mL HA (high-molecular-weight: 2700 kDa) injec-
tions, over a period of 1 week, in a total of 61 patients
with enthesopathies: 16 with lateral epicondylitis,14
with patellar tendinopathy, 15 with insertional Achilles
tendinopathy, and 16 with plantar fasciitis39. They ob-
served a significant decrease of pain (VAS) for the 4
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sites (-2.20 ± 2.26 for the 4 sites overall), suggesting
the efficacy of injections of HA for enthesopathies in
the short-term.
Discussion
Tendinopathies are very common condition in sports
and working population1. Tendinopathy and tenosyn-
ovitis disturbs tendon gliding. The application of HA
can reduce tendon glide resistance10-14. Several earli-
er studies have shown the link between the inhibition
of fibroblast proliferation and a reduction in type III
collagen concentration in the tendon, with a reduction
in the formation of adhesions at the tendon healing
site40-42. By limiting the proliferation of fibroblasts and
by stabilizing the concentration of type III collagen,
HA may reduce the risk of adhesions10-12. It is still
discuss if HA can stimulate or not the synthesis of
type I collagen to improve the tendon structure and
resistance5,18, but it is demonstrated that HA improve
cell viability and proliferation17,18. HA appears to in-
hibit the expression of key intermediaries for the in-
flammatory signaling pathways (NF-kB), in a dose-
dependent manner19,43. By reducing the expression
of proinflammatory factors, adding exogenous HA re-
duces the fragmentation of endogenous HA and stim-
ulates synovial synthesis of endogenous HA16,26,36.
Concerning the therapeutic protocol for HA injections
for tendinopathies, comparatively to other recent
treatments for these conditions, where post-injection
rehabilitation could be crucial44, such as PRP for ex-
ample45, only 1 or 2 injections alone are described for
HA treatments30-32,35-39. However, comparatively to
PRP treatments, where it exist a wide variability in
the administered product46,47, the molecular weight
and the concentration of HA are known18; high mole-
cular weight HA seems to have a better effect on ten-
dons18 in the short-term.
Conclusion
Some in vitro and animal in vivo studies demonstrate
encouraging results in terms of the ability of HA to
encourage tendon gliding and to reduce adhesions
as well as creating better tendon architectural organ-
isation. Moreover, the injection of HA may limit the
proinflammatory effect by restoring viscoelasticity
and by stimulating the endogenous synthesis of HA.
These laboratory observations appear to be support-
ed by limited but encouraging short-term clinical re-
sults on pain and function as well as on the return to
sport. However, controlled randomised studies are
still needed.
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